Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).

Haruka MaedaNobuo SaitoAtaru IgarashiMasayuki IshidaMayumi TeradaShingo MasudaRyosuke OsawaNaoto HosokawaKei NakashimaHiroshi KamuraHaruki ImuraHiroki InoueSuguru MatsuzakaYukihiro SugimotoOsamu KuwamitsuIori MotohashiToru MorikawaRentaro OdaYuiko HoshinaTakashi MatonoOsamu TeshigaharaEiichiro SandoSadaharu AsamiSatoshi KudoNoboru AkizukiYoshikazu MutoTomoichiro HayakawaTomoo KishabaYasuji OharaYoshinao KuboMotoi SuzukiKonosuke Morimoto

Published in: Expert review of vaccines (2024)

mRNA booster vaccination provided moderate protection against symptomatic infections and high-level protection against severe diseases during the BA.5 epidemic in Japan.

Keyphrases

sars cov
respiratory syndrome coronavirus
randomized controlled trial
systematic review
early onset
public health
drug induced